Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use COMIRNATY safely and effectively. See full prescribing information for COMIRNATY. COMIRNATY® (COVID-19 Vaccine, mRNA) injectable suspension, for intramuscular use2026-2027 FormulaInitial U.S. Approval: 2021
Medication labelWhy this: Advisory · dailymed-other
COMIRNATY is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COMIRNATY is approved for use in individuals who are: • 65 years of age and older, or • 5 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
- generic_name
- covid-19 vaccine, mrna
- product_names
- COVID-19 Vaccine, mRNA
- ndc
- 0069-2528, 0069-2501, 0069-2631, 0069-2609, 0069-2528-01, 0069-2528-10, 0069-2501-01, 0069-2501-10, 0069-2631-01, 0069-2631-10, 0069-2609-01, 0069-2609-10
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en